Evidence
- beer_2014_rct_enzalutamide-vs-placebo-mcrpc-prevail
- de-bono_2011_rct_abiraterone-plus-prednisone-vs-placebo-cou-aa-301
- denosumab20050103_2020_rct_denosumab-prolongs-time-to-first-sre
- fizazi_2011_rct_denosumab-vs-zoledronic-acid-mcrpc
- saad_2002_rct_zoledronic-acid-4mg-vs-placebo-sre-mcrpc
- saad_2002_rct_zoledronic-acid-4mg-vs-placebo-sre-mcrpc
- scher_2012_rct_enzalutamide-vs-placebo-affirm
Protocols
- medication-cancer-prostate-abiraterone-prednisone-daily
- medication-cancer-prostate-enzalutamide-daily-oral-generic
- medication-osteoporosis-denosumab
- medication-osteoporosis-denosumab-subcutaneous-monthly-generic
- medication-osteoporosis-zoledronic-acid-intravenous-every-three-week-dose-reduced-generic
- medication-osteoporosis-zoledronic-acid-intravenous-every-three-week-generic